Clinical trials for Stomach and esophageal cancer

157 currently recruiting clinical trials
Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT06475352
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
37 recruiting sites
UNICANCER
Phase 2 Stomach and esophageal cancer #NCT06059495
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Radiotherapy
1 recruiting site
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06726148 #2024-517281-42-00
Phase I - cancer amplifié CCNE1
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Novartis
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07288359 #2025-521911-38-00
Phase I autres tumeurs avec amplification du gène CCNE1
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Novartis
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07397338 #2025-524623-50-00
Cohorte Tumeur solide /CRC (bras C pour l'expansion de dose de la partie 2)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS RAS
Required number of previous lines of therapy
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04939610 #2023-508995-12-01
Phase 1: Escalade de dose
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B4
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Stomach and esophageal cancer #NCT06780111 #2024-514273-22-00
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05706129 #2023-504254-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06439888
Required disease stage
Metastatic Metastatic Castration-resistant
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris